Shrug Off the Market and Consider Exelixis

Yesterday the FDA granted Exelixis (EXEL) a breakthrough designation for their wholly owned drug compound cabozantinib.  The compound will be a a potential treatment for advanced renal cell carcinoma.  The NIH reports approximately 60,000 new cases of renal cancer a year and 14,000 deaths from the disease.Currently there are two drugs on the market right now…

Vores uafhængige analyser er tilgængelig mod betaling / This content is for David Zickafoose Fundmanager Subscription members only.
Log In Register